A Study to Learn How the Study Medicine Called PF-08653944 is Taken up Into the Blood in Adults With Overweight or Obesity

Part of paid clinical trials in New Haven, Connecticut.

Sponsor
Pfizer
Study ID
NCT07400679
Phase
PHASE1
Status
Active Not Recruiting

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Accepted

Interventions

  • PF-08653944 — DRUG
    Solution for injection

Study Details

This study is being done to learn how the study medicine affects the body and how safe it is for people who take it. The researchers will look at a number of health tests, including blood tests such as calcitonin, amylase, and lipase, because similar medicines have sometimes caused changes in these tests. This study is seeking participants who are: * Adults who are obese or overweight with weight-related health conditions, and * Meet health and other checks assessed by the study doctor. The study team will give a single dose of the study treatment at the clinic to the participants. At each study visit, blood samples will be collected, vital signs will be checked, and the study team will ask about any reactions or health changes. Vital signs are basic measurements that show how well the body is working. They help the study team quickly understand a participant's overall health. These usually include body temperature, heart rate, breathing rate, and blood pressure. The study involves multiple clinic visits at a study site over the length of the study. The information collected will help researchers understand how the study medicine works and whether it is safe.

Key Dates

Start date
Feb 4, 2026
Status verified
May 2026
Primary completion
Sep 18, 2026
Completion
Sep 18, 2026

Study Design

Enrollment
54 participants (actual)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
BASIC_SCIENCE

Arms

  • Experimental: Treatment 1
    Participants will receive a single subcutaneous (SC) dose of PF-08653944 on Day 1 administered to the abdomen.
  • Experimental: Treatment 2
    Participants will receive a single SC dose of PF-08653944 on Day 1 administered to the thigh.
  • Experimental: Treatment 3
    Participants will receive a single SC dose of PF-08653944 on Day 1 administered to the upper arm.
  • Experimental: Treatment 4 (Optional)
    Japanese participants will receive a single SC dose of PF-08653944 on Day 1 administered to the abdomen.

Primary Outcome Measure

Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve (AUC) of PF-08653944 [ Time Frame: Up to 85 days ]

Locations (1)

FacilityCityStateZIPSite coordinators
New Haven Clinical Research UnitNew HavenConnecticut06511-

Find similar trials in New Haven, CT

By condition
Obesity / overweight
By specialty
EndocrinologyMetabolic healthWeight loss
By research site
New Haven Clinical Research Unit· New Haven, CT

Related Studies